50: Statistical Methods for Composite Endpoints Accounting for Severity of Events

Shahidul Islam Co-Author
Biostatistics Unit, Northwell Health, New Hyde Park, NY
 
Anand Rajan, MPH Co-Author
NYU Grossman Long Island School of Medicine
 
Xiwei Yang Co-Author
NYU Grossman Long Island School of Medicine
 
Jessica Guillaume Co-Author
NYU Grossman Long Island School of Medicine
 
Mariana Murea Co-Author
Wake Forest University School of Medicine
 
Jasmin Divers Co-Author
NYU Long Island School of Medicine
 
Nihan Gencerliler First Author
NYU Grossman Long Island School of Medicine
 
Nihan Gencerliler Presenting Author
NYU Grossman Long Island School of Medicine
 
Monday, Aug 4: 10:30 AM - 12:20 PM
1915 
Contributed Posters 
Music City Center 
Composite endpoints (CE), combining death and non-fatal events, are often used in randomized clinical trials when the incidence of individual events is low. CEs typically involve different event types, implying considerable differences in event severity and cost to the patient and healthcare system. Time-to-first-event analysis treats all components of the CE equally and is heavily influenced by short-term events, potentially misrepresenting clinical significance. Novel statistical methods have been introduced to overcome these limitations, including competing risk regression (CR), negative binomial (NB), and win ratio (WR). Joint frailty models (JFM) can account for the unobserved heterogeneity in the survival and informative censoring distributions associated with different event types and patient death. A simulation approach will be used to compare the performance of four methods – CR, NB, WR, and JFM. Performance will be assessed based on type I error, power, and ease of clinical interpretation. Best-performing approaches will then be applied to analyze the Comparative Effectiveness of an Individualized Hemodialysis model vs Conventional Hemodialysis (TwoPlus) trial.

Keywords

composite endpoints

competing risk

negtative binomial

win ratio

joint frailty models

simulation 

Main Sponsor

Biopharmaceutical Section